Ocera Therapeutics, Inc.
Healthcare · Pharmaceutical Preparations · CA · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY16 | FY15 | FY14 | FY13 | FY12 | FY11 | |
|---|---|---|---|---|---|---|
| Revenue | $609,000 | $133,000 | $341,000 | $85,000 | $0 | $2.3M |
| Operating income | — | — | — | — | −$7.5M | −$3.1M |
| Net income | −$7.5M | −$6.7M | −$23.4M | −$17.5M | −$1.1M | −$3.4M |
| Total assets | $29.6M | $44.7M | $53.1M | $51.8M | $2.4M | $44.7M |
| Total liabilities | $13.9M | $13.3M | $2.9M | $6.7M | $3.5M | $20.2M |
| Equity | $15.7M | $31.4M | $50.1M | $45.1M | −$62.8M | −$59.6M |
| EPS (diluted) | — | — | — | — | — | — |
| Shares out. | 21.3M | 19.7M | 15.5M | 27.6M | 24.6M | 24.6M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2016- Operating margin
- —
- Net margin
- −1233.8%
- Return on equity
- −47.7%
- Return on assets
- −25.4%
- Return on capital (ROCE)
- —
- Liabilities / assets
- 46.9%
- Debt / equity
- 0.88×
- Book value / share
- $0.74
- Revenue growth (YoY)
- 357.9%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2016- Accruals / assets
- 49.2%high accruals
- Piotroski F-Score
- 1/8weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 3 warning● 2 good- Reported a net loss
- Negative operating cash flow
- High accruals — earnings-quality risk
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Domain Associates10% owner | Dec 11, 2017 | D | 47,963 | — |
| Dp Vi Associates, L.P.10% owner | Dec 11, 2017 | D | 15,731 | — |
| Domain Partners Vi, L.P.10% owner | Dec 11, 2017 | D | 1.9M | — |
| Dp Viii Associates, L.P.10% owner | Dec 11, 2017 | D | 7,333 | — |
| Domain Partners Viii, L.P.10% owner | Dec 11, 2017 | D | 988,285 | — |
| Grais Linda SOfficer — President and CEO | Dec 11, 2017 | D | 230,000 | $1.52 |
| Kjellson Nina SDirector | Dec 11, 2017 | D | 12,500 | $1.52 |
| Bukofzer StanOfficer — Chief Medical Officer | Dec 11, 2017 | D | 2,500 | $1.52 |
| James Steven PDirector | Dec 11, 2017 | D | 12,500 | $1.52 |
| Byrnes MichaelOfficer — CFO and Treasurer | Dec 11, 2017 | D | 13,000 | $1.52 |
| Dere Willard HDirector | Dec 11, 2017 | D | 12,500 | $1.52 |
| Vanlent AnneDirector | Dec 11, 2017 | D | 12,500 | $1.52 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Terminated a material agreement · Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylaws · Other material eventDec 11, 2017
- Entered a material agreement · Amended charter or bylaws · Regulation FD disclosureNov 2, 2017
- Delisting / listing-standard noticeSep 29, 2017
- Delisting / listing-standard noticeAug 4, 2017
- Results of operationsAug 1, 2017
- Shareholder voteJun 22, 2017
- Results of operationsMay 9, 2017
- Director / officer changeMar 31, 2017
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SC 13G/AFeb 14, 2018
- SC 13G/AAMENDMENT NO. 1 TO SCHEDULE 13GFeb 14, 2018
- 15-12BDec 21, 2017
- SC 13D/ADec 21, 2017
- SC 13D/AFORM SC 13D/A FOR OCERA THERAPEUTICS, INC. BY DOMAIN PARTNERS VIII, L.P.Dec 14, 2017
- EFFECTDec 13, 2017
- EFFECTDec 13, 2017
- EFFECTDec 13, 2017
- 4PRIMARY DOCUMENTDec 13, 2017
- 4PRIMARY DOCUMENTDec 13, 2017
- 4PRIMARY DOCUMENTDec 13, 2017
- 4PRIMARY DOCUMENTDec 13, 2017
- 4PRIMARY DOCUMENTDec 13, 2017
- 4FORM 4 SUBMISSIONDec 11, 2017
- 4FORM 4 SUBMISSIONDec 11, 2017
Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.